日本全国调查:冷吡啉相关周期性综合征的临床特征及卡那单抗长期真实世界疗效与耐受性
日本全国回顾性调查纳入101例冷吡啉相关周期性综合征(CAPS)患者,评估卡那单抗等IL-1抑制剂的真实世界疗效与安全性。73.7%患者经卡那单抗达到完全缓解,早期治疗与更好听觉结局相关,但23.7%未达炎症缓解且器官损害进展,部分患者治疗中出现IBD。
要点
- 卡那单抗治疗使73.7%的CAPS患者达到完全缓解,早期干预与更好听觉结局相关。
- 23.7%患者未达炎症缓解且器官损害关键性恶化,其中2例在接受高剂量卡那单抗治疗期间死亡。
- 4例炎症未缓解患者在卡那单抗治疗期间发生未分类炎症性肠病(IBD)。
核心结论
- 早期启动卡那单抗抗IL-1治疗有利于改善疾病预后,但部分患者即使血清卡那单抗浓度高仍未达缓解。
- CAPS患者在接受卡那单抗治疗后可能发生IBD。
研究设计与样本
- 回顾性收集临床信息,并分析卡那单抗及细胞因子的血清浓度,共纳入101例CAPS患者。
主要发现
- 101例患者中86例携带种系杂合突变、15例携带体细胞嵌合突变,共识别39种突变类型。
- 6例患者(占全部患者的5.9%)死亡,其中4例死于CAPS相关症状。
- 73.7%的患者经卡那单抗达到完全缓解,家族性寒冷自身炎症综合征、Muckle-Wells综合征和慢性婴儿神经皮肤关节综合征/新生儿起病多系统炎症性疾病中分别有100%、79.6%和44.4%达到完全缓解。
- 23.7%的患者未达炎症缓解且器官损害关键性恶化,其中2例在接受高剂量卡那单抗治疗期间死亡。
- 卡那单抗和细胞因子浓度的血清学分析显示,治疗反应差与卡那单抗浓度不足无关。
临床怎么用
- 卡那单抗治疗可使部分患者的骨骺过度生长进展稳定,并改善身高增长、视力和肾功能。
- 对卡那单抗单药治疗未解决的IBD及CAPS相关症状,卡那单抗联合抗肿瘤坏死因子-α药物的双生物制剂治疗有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We assess the clinical characteristics of patients with cryopyrin-associated periodic syndrome (CAPS) in Japan and evaluate the real-world efficacy and safety of interleukin-1 (IL-1) inhibitors, primarily canakinumab. METHODS: Clinical information was collected retrospectively, and serum concentrations of canakinumab and cytokines were analyzed. RESULTS: A total of 101 patients were included, with 86 and 15 carrying heterozygous germline and somatic mosaic mutations, respectively. We identified 39 mutation types, and the common CAPS-associated symptoms corresponded with those in previous reports. Six patients (5.9% of all patients) died, with four of the deaths caused by CAPS-associated symptoms. Notably, 73.7% of patients (100%, 79.6%, and 44.4% of familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and chronic infantile neurological cutaneous articular syndrome/neonatal onset multisystem inflammatory disease, respectively) achieved complete remission with canakinumab, and early therapeutic intervention was associated with better auditory outcomes. In some patients, canakinumab treatment stabilized the progression of epiphysial overgrowth and improved height gain, visual acuity, and renal function. However, 23.7% of patients did not achieve inflammatory remission with crucial deterioration of organ damage, with two dying while receiving high-dose canakinumab treatment. Serological analysis of canakinumab and cytokine concentrations revealed that the poor response was not related to canakinumab shortage. Four inflammatory nonremitters developed inflammatory bowel disease (IBD)-unclassified during canakinumab treatment. Dual biologic therapy with canakinumab and anti-tumor necrosis factor-α agents was effective for IBD- and CAPS-associated symptoms not resolved by canakinumab monotherapy. CONCLUSION: This study provides one of the largest epidemiologic data sets for CAPS. Although early initiation of anti-IL-1 treatment with canakinumab is beneficial for improving disease prognosis, some patients do not achieve remission despite a high serum concentration of canakinumab. Moreover, IBD may develop in CAPS after canakinumab treatment.
引用
- Miyamoto T, Izawa K, Masui S, et al. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey. Arthritis Rheumatol. 2024. PMID: 38268504. doi:10.1002/art.42808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。